Teladoc Health, Inc. (TDOC) has a negative trailing P/E of -4.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 37.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -21.97%, forward earnings yield 2.67%.
Criteria proven by this page:
Overall SharesGrow Score: 44/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -9.4 | 0.24 | 3.03 | 5.67 | - |
| 2017 | -18.1 | -1.76 | 3.46 | 8.28 | - |
| 2018 | -33.6 | 1.41 | 3.22 | 7.81 | - |
| 2019 | -60.8 | 9.94 | 5.93 | 10.87 | - |
| 2020 | -37.3 | -0.13 | 1.14 | 16.54 | - |
| 2021 | -33.6 | 0.68 | 0.90 | 7.09 | - |
| 2022 | -0.3 | 0.00 | 1.65 | 1.59 | - |
| 2023 | -15.9 | 0.16 | 1.50 | 1.34 | - |
| 2024 | -1.5 | 0.00 | 1.04 | 0.60 | - |
| 2025 | -6.2 | 0.08 | 0.89 | 0.49 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.75 | $123.16M | $-74.22M | -60.3% |
| 2017 | $-1.93 | $233.28M | $-106.78M | -45.8% |
| 2018 | $-1.47 | $417.91M | $-97.08M | -23.2% |
| 2019 | $-1.38 | $553.31M | $-98.86M | -17.9% |
| 2020 | $-5.36 | $1.09B | $-485.14M | -44.3% |
| 2021 | $-2.73 | $2.03B | $-428.79M | -21.1% |
| 2022 | $-84.60 | $2.41B | $-13.66B | -567.5% |
| 2023 | $-1.34 | $2.6B | $-220.37M | -8.5% |
| 2024 | $-5.87 | $2.57B | $-1B | -39% |
| 2025 | $-1.14 | $2.53B | $-200.32M | -7.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.90 | $-1.13 – $-0.55 | $2.51B | $2.48B – $2.53B | 11 |
| 2027 | $-0.74 | $-1.16 – $-0.39 | $2.54B | $2.48B – $2.63B | 10 |
| 2028 | $-0.72 | $-1.31 – $0.36 | $2.58B | $2.58B – $2.58B | 7 |
| 2029 | $-0.16 | $-0.16 – $-0.15 | $2.68B | $2.63B – $2.74B | 2 |
| 2030 | $0.14 | $0.14 – $0.14 | $2.87B | $2.81B – $2.93B | 5 |
